Despite a challenging financial landscape, Canaccord Genuity maintained a “Buy” rating for Biodesix, Inc. (NASDAQ:BDSX).
Biodesix reported a quarterly loss of $0.08 per share, an improvement from the previous year’s loss of $0.14 per share.
Revenue for Q1 2025 was $17.96 million, a 21% increase from the same quarter last year, driven by lung diagnostic testing and services.
Biodesix, Inc. (NASDAQ:BDSX) is a diagnostic solutions company specializing in lung diagnostics and services. Despite a challenging financial landscape, Canaccord Genuity maintained a “Buy” rating for BDSX on May 14, 2025, even though the stock was rated as “hold” by others. At that time, the stock was priced at $0.22, reflecting a significant decrease from its previous highs.
During the Q1 2025 earnings call, Biodesix reported a quarterly loss of $0.08 per share, aligning with the Zacks Consensus Estimate. This was an improvement from the previous year’s loss of $0.14 per share. The company has consistently exceeded consensus EPS estimates in three of the last four quarters, showcasing its ability to manage expectations effectively.
Biodesix’s revenue for Q1 2025 was $17.96 million, which fell short of the Zacks Consensus Estimate by 7.19%. However, this represented a 21% increase from the $14.82 million reported in the same quarter last year. The company has only surpassed consensus revenue estimates once in the last four quarters, indicating challenges in meeting market expectations.
CEO Scott Hutton emphasized the company’s progress towards its 2025 goals, focusing on revenue growth, operational efficiencies, and pipeline advancement. The revenue growth was driven by lung diagnostic testing and services, with lung diagnostics revenue increasing by 18%, marking the 16th consecutive quarter of over 15% growth.
The stock price of BDSX has seen a significant decrease of approximately 38.74%, with a current price of $0.22. The stock has fluctuated between $0.195 and $0.3003 today, with a 52-week high of $2.04 and a low of $0.195. The company’s market capitalization is approximately $32.2 million, with a trading volume of 4,148,055 shares.
